IDEAYA Biosciences, Inc. (IDYA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, IDEAYA Biosciences reported revenue of $218.7M, up 3024.4% from $7.0M the year before. Net income was -$113.7M (a -52.0% net margin), or -$1.28 per diluted share. Operating margin was -72.8%. Operating activities generated -$71.1M of cash, leaving -$73.5M of free cash flow. At fiscal year end, IDEAYA Biosciences held $1.11B in total assets against $86.4M in total liabilities, including $112.8M of cash and equivalents.
Open the full interactive IDEAYA Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
IDEAYA Biosciences Key Stats
| Share Price | $34.26 |
|---|---|
| Market Cap | $3.15B |
| 52-Week Range | $26.77 – $42.48 |
| Shares Outstanding | 92.1 million (basic, 2026 Q2) |
IDEAYA Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M |
| Operating Income | -$35.3M | -$50.3M | -$62.5M | -$134.4M | -$327.0M | -$159.3M |
| Pre-Tax Income | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| Diluted EPS | -$1.40 | -$1.41 | -$1.42 | -$1.96 | -$3.36 | -$1.28 |
IDEAYA Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $207.8M | $10.9M | $6.6M | $8.9M |
| Net Income | $119.2M | -$83.3M | -$98.5M | -$112.5M |
| Diluted EPS | $1.33 | -$0.94 | -$1.11 | -$1.22 |
IDEAYA Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.0M | $92.0M | $68.6M | $157.0M | $84.4M | $112.8M |
| Current Assets | $288.6M | $251.0M | $370.5M | $532.6M | $689.7M | $666.7M |
| Total Assets | $298.3M | $381.3M | $388.0M | $649.3M | $1.12B | $1.11B |
| Current Liabilities | $38.6M | $45.2M | $31.7M | $27.1M | $46.1M | $58.8M |
| Total Liabilities | $100.0M | $79.8M | $38.5M | $28.2M | $64.9M | $86.4M |
| Shareholders' Equity | $198.3M | $301.5M | $349.5M | $621.1M | $1.06B | $1.02B |
IDEAYA Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $55.5M | -$55.8M | -$87.2M | -$115.2M | -$247.6M | -$71.1M |
| Cash From Investing | -$146.2M | -$69.7M | -$33.4M | -$158.5M | -$502.6M | $70.0M |
| Cash From Financing | $128.8M | $145.5M | $97.2M | $362.7M | $677.6M | $29.8M |
| Free Cash Flow | $55.0M | -$58.4M | -$90.6M | -$117.6M | -$251.4M | -$73.5M |
Figures from IDEAYA Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full IDEAYA Biosciences financials page for every line item.
IDEAYA Biosciences Company Profile
| Ticker | IDYA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001676725 |
Frequently Asked Questions
What was IDEAYA Biosciences' revenue in fiscal 2025?
IDEAYA Biosciences (IDYA) reported revenue of $218.7M for fiscal 2025.
What is IDEAYA Biosciences' annual revenue history?
IDEAYA Biosciences' annual revenue by fiscal year: 2020: $19.5M; 2021: $27.9M; 2022: $50.9M; 2023: $23.4M; 2024: $7.0M; 2025: $218.7M.
What was IDEAYA Biosciences' net income in fiscal 2025?
IDEAYA Biosciences reported net income of -$113.7M for fiscal 2025.
What was IDEAYA Biosciences' earnings per share (EPS) in fiscal 2025?
IDEAYA Biosciences' diluted EPS was -$1.28 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did IDEAYA Biosciences generate in fiscal 2025?
IDEAYA Biosciences generated -$73.5M of free cash flow in fiscal 2025.
What was IDEAYA Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), IDEAYA Biosciences reported revenue of $8.9M.
How many shares of IDEAYA Biosciences are outstanding?
IDEAYA Biosciences reported a weighted average of 92.1 million basic shares outstanding in 2026 Q2.
What is IDEAYA Biosciences' market cap?
Based on its latest closing price, IDEAYA Biosciences (IDYA) has a market capitalization of about $3.15B.
When does IDEAYA Biosciences' fiscal year end?
IDEAYA Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is IDEAYA Biosciences headquartered?
IDEAYA Biosciences lists its business address in South San Francisco, California in its SEC filings.